The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA) in Nepal.
Latest Posts
- Advanced Module Public Health Systems Challenges and Opportunities: The Case of Nepal
- UiB Dhulikhel Hospital PhD Scholarships Opportunity
- Call for Applications! Master in PHC Management and Social Health Protection
- The Gadjah Mada International Fellowship (GMIF) Degree Program
- World Health Day 2024 Art Competition
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at blog.publichealthupdate@gmail.com.
#StayUpdated